BRIEF-Regenxbio Presents Positive Twelve-Month Pivotal Data From Phase I/Ii/Iii Campsiite® Trial Of Rgx-121 For Treatment Of Mps Ii

Reuters

Sep 05

Regenxbio Inc RGNX.O:

REGENXBIO PRESENTS POSITIVE TWELVE-MONTH PIVOTAL DATA FROM PHASE I/II/III CAMPSIITE® TRIAL OF RGX-121 FOR TREATMENT OF MPS II
REGENXBIO INC - RGX-121 IMPROVES OUTCOMES FOR MPS II PATIENTS
REGENXBIO INC - PRIMARY ENDPOINT OF CSF HS D2S6 REDUCTION MET
REGENXBIO INC - FDA DECISION ON RGX-121 EXPECTED BY FEBRUARY 8, 2026

Source text: ID:nPn5glkbna

Further company coverage: RGNX.O

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2565552174"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2565552174\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2565552174?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-05 19:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2565552174","market":"us","top_or_hot":-1,"title":"BRIEF-Regenxbio Presents Positive Twelve-Month Pivotal Data From Phase I/Ii/Iii Campsiite® Trial Of Rgx-121 For Treatment Of Mps Ii","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Regenxbio Presents Positive Twelve-Month Pivotal Data From Phase I/Ii/Iii Campsiite® Trial Of Rgx-121 For Treatment Of Mps Ii</title></head><body><p><a href=\"https://laohu8.com/S/RGNX\">Regenxbio Inc</a> <span>RGNX.O</span>:</p><ul><li><p>REGENXBIO PRESENTS POSITIVE TWELVE-MONTH PIVOTAL DATA FROM PHASE I/II/III CAMPSIITE® TRIAL OF RGX-121 FOR TREATMENT OF MPS II</p></li><li><p>REGENXBIO INC - RGX-121 IMPROVES OUTCOMES FOR MPS II PATIENTS</p></li><li><p>REGENXBIO INC - PRIMARY ENDPOINT OF CSF HS D2S6 REDUCTION MET</p></li><li><p>REGENXBIO INC - FDA DECISION ON RGX-121 EXPECTED BY FEBRUARY 8, 2026</p></li></ul><p>Source text: <span>ID:nPn5glkbna</span></p><p>Further company coverage: <span>RGNX.O</span></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Regenxbio Presents Positive Twelve-Month Pivotal Data From Phase I/Ii/Iii Campsiite® Trial Of Rgx-121 For Treatment Of Mps Ii</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Regenxbio Presents Positive Twelve-Month Pivotal Data From Phase I/Ii/Iii Campsiite® Trial Of Rgx-121 For Treatment Of Mps Ii\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-05 19:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Regenxbio Presents Positive Twelve-Month Pivotal Data From Phase I/Ii/Iii Campsiite® Trial Of Rgx-121 For Treatment Of Mps Ii</title></head><body><p><a href=\"https://laohu8.com/S/RGNX\">Regenxbio Inc</a> <span>RGNX.O</span>:</p><ul><li><p>REGENXBIO PRESENTS POSITIVE TWELVE-MONTH PIVOTAL DATA FROM PHASE I/II/III CAMPSIITE® TRIAL OF RGX-121 FOR TREATMENT OF MPS II</p></li><li><p>REGENXBIO INC - RGX-121 IMPROVES OUTCOMES FOR MPS II PATIENTS</p></li><li><p>REGENXBIO INC - PRIMARY ENDPOINT OF CSF HS D2S6 REDUCTION MET</p></li><li><p>REGENXBIO INC - FDA DECISION ON RGX-121 EXPECTED BY FEBRUARY 8, 2026</p></li></ul><p>Source text: <span>ID:nPn5glkbna</span></p><p>Further company coverage: <span>RGNX.O</span></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RGNX","symbol_name":"Regenxbio Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250905:nTUA5XTNWX:1","article_id":"2565552174","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2565552174","pubTimestamp":1757070353,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Regenxbio Presents Positive Twelve-Month Pivotal Data From Phase I/Ii/Iii Campsiite Trial Of Rgx-121 For Treatment Of Mps IiRegenxbio Inc RGNX.O:REGENXBIO PRESENTS POSITIVE TWELVE-MONTH PIVOTAL ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RGNX":"Regenxbio Inc","BK4139":"生物科技","BK4505":"高瓴资本持仓","BK4563":"昨日强势股"},"translate_title":"简介-Regenxbio公布了Campsiite I/Ii/Iii期积极的12个月关键数据®Rgx-121治疗Mps Ii的试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RGNX":0.9},"content_text":"BRIEF-Regenxbio Presents Positive Twelve-Month Pivotal Data From Phase I/Ii/Iii Campsiite® Trial Of Rgx-121 For Treatment Of Mps IiRegenxbio Inc RGNX.O:REGENXBIO PRESENTS POSITIVE TWELVE-MONTH PIVOTAL DATA FROM PHASE I/II/III CAMPSIITE® TRIAL OF RGX-121 FOR TREATMENT OF MPS IIREGENXBIO INC - RGX-121 IMPROVES OUTCOMES FOR MPS II PATIENTSREGENXBIO INC - PRIMARY ENDPOINT OF CSF HS D2S6 REDUCTION METREGENXBIO INC - FDA DECISION ON RGX-121 EXPECTED BY FEBRUARY 8, 2026Source text: ID:nPn5glkbnaFurther company coverage: RGNX.O","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}